OMERS ADMINISTRATION Corp Has $5.84 Million Holdings in Stryker Corporation $SYK

OMERS ADMINISTRATION Corp lifted its position in Stryker Corporation (NYSE:SYK) by 25.4% in the 1st quarter, Holdings Channel reports. The fund owned 17,766 shares of the medical technology company’s stock after buying an additional 3,598 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Stryker were worth $5,838,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Godfrey Financial Associates Inc. purchased a new position in Stryker during the 4th quarter worth approximately $26,000. Sankala Group LLC purchased a new stake in shares of Stryker in the fourth quarter valued at $26,000. United Financial Planning Group LLC purchased a new stake in shares of Stryker in the third quarter valued at $27,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker in the fourth quarter worth $27,000. Finally, DJE Kapital AG acquired a new stake in shares of Stryker in the fourth quarter worth $28,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the sale, the vice president directly owned 13,137 shares of the company’s stock, valued at $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by corporate insiders.

Stryker Trading Up 0.1%

NYSE SYK opened at $330.69 on Monday. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.14. The firm’s fifty day simple moving average is $314.69 and its 200-day simple moving average is $335.57. The company has a market capitalization of $126.78 billion, a PE ratio of 38.27, a price-to-earnings-growth ratio of 2.12 and a beta of 0.77.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter last year, the firm earned $2.84 EPS. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 14.99 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is currently 40.74%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Canaccord Genuity Group dropped their price target on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Sanford C. Bernstein set a $410.00 price objective on Stryker in a research report on Friday, May 1st. BMO Capital Markets started coverage on Stryker in a research note on Wednesday, July 8th. They set an “outperform” rating and a $369.00 target price on the stock. Argus set a $370.00 target price on Stryker in a report on Thursday, July 9th. Finally, Citigroup reduced their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $392.52.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.